As of 2025-09-16, the EV/EBITDA ratio of Recursion Pharmaceuticals Inc (RXRX) is -2.70. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RXRX's latest enterprise value is 1,568.73 mil USD. RXRX's TTM EBITDA according to its financial statements is -581.79 mil USD. Dividing these 2 quantities gives us the above RXRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.4x - 13.3x | 10.9x |
| Forward P/E multiples | 12.0x - 19.1x | 15.6x |
| Fair Price | (14.92) - (16.67) | (16.53) |
| Upside | -412.9% - -449.4% | -446.6% |
| Date | EV/EBITDA |
| 2025-09-12 | -2.74 |
| 2025-09-11 | -2.76 |
| 2025-09-10 | -2.52 |
| 2025-09-09 | -2.64 |
| 2025-09-08 | -2.58 |
| 2025-09-05 | -2.58 |
| 2025-09-04 | -2.51 |
| 2025-09-03 | -2.59 |
| 2025-09-02 | -2.61 |
| 2025-08-29 | -2.64 |
| 2025-08-28 | -2.77 |
| 2025-08-27 | -2.79 |
| 2025-08-26 | -2.74 |
| 2025-08-25 | -2.74 |
| 2025-08-22 | -2.82 |
| 2025-08-21 | -2.70 |
| 2025-08-20 | -2.70 |
| 2025-08-19 | -2.94 |
| 2025-08-18 | -3.26 |
| 2025-08-15 | -3.44 |
| 2025-08-14 | -3.35 |
| 2025-08-13 | -3.39 |
| 2025-08-12 | -3.17 |
| 2025-08-11 | -3.08 |
| 2025-08-08 | -3.14 |
| 2025-08-07 | -3.17 |
| 2025-08-06 | -3.23 |
| 2025-08-05 | -3.26 |
| 2025-08-04 | -3.47 |
| 2025-08-01 | -3.38 |
| 2025-07-31 | -3.58 |
| 2025-07-30 | -3.47 |
| 2025-07-29 | -3.58 |
| 2025-07-28 | -3.85 |
| 2025-07-25 | -3.98 |
| 2025-07-24 | -3.81 |
| 2025-07-23 | -3.94 |
| 2025-07-22 | -4.02 |
| 2025-07-21 | -3.91 |
| 2025-07-18 | -3.49 |
| 2025-07-17 | -3.26 |
| 2025-07-16 | -3.16 |
| 2025-07-15 | -3.03 |
| 2025-07-14 | -3.08 |
| 2025-07-11 | -3.08 |
| 2025-07-10 | -3.40 |
| 2025-07-09 | -3.31 |
| 2025-07-08 | -3.14 |
| 2025-07-07 | -2.82 |
| 2025-07-03 | -3.07 |